| Fatima Corbeta Gerard, ARNP | |
|
1006 N H St, Aberdeen, WA 98520-2521 | |
| (360) 537-6332 | |
| Not Available |
| Full Name | Fatima Corbeta Gerard |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 4 Years |
| Location | 1006 N H St, Aberdeen, Washington |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548881121 | NPI | - | NPPES |
| AP61090955 | Other | WA | WASHINGTON STATE LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 363LF0000X | Nurse Practitioner - Family | AP61090955 (Washington) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Harbors Home Health / Hospice | Hoquiam, WA | Home health agency |
| Grays Harbor Community Hospital | Aberdeen, WA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Grays Harbor Community Hospital | 3577462365 | 70 |
News Archive
The Associated Press: "Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year. The Food and Drug Administration released recommendations Tuesday night designed to improve oversight of the U.S. device industry, including the government's ability to revoke approval for products that prove unsafe or ineffective" (Perrone, 8/3).
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.
The results from comparative analysis of this population demonstrate the risk of developing dementia increased by 50% for subjects who consumed benzodiazepines during the follow-up period, compared with those who had never used benzodiazepines.
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.
› Verified 9 days ago
| Entity Name | Grays Harbor Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154378859 PECOS PAC ID: 3577462365 Enrollment ID: O20031231000081 |
News Archive
The Associated Press: "Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year. The Food and Drug Administration released recommendations Tuesday night designed to improve oversight of the U.S. device industry, including the government's ability to revoke approval for products that prove unsafe or ineffective" (Perrone, 8/3).
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.
The results from comparative analysis of this population demonstrate the risk of developing dementia increased by 50% for subjects who consumed benzodiazepines during the follow-up period, compared with those who had never used benzodiazepines.
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fatima Corbeta Gerard, ARNP 1006 N H St Fl 3, Aberdeen, WA 98520-2521 Ph: (360) 537-6322 | Fatima Corbeta Gerard, ARNP 1006 N H St, Aberdeen, WA 98520-2521 Ph: (360) 537-6332 |
News Archive
The Associated Press: "Makers of X-ray machines, drug pumps and other medical devices would have to submit more safety information to win federal approval under a proposal designed to tighten regulation of thousands of products reviewed each year. The Food and Drug Administration released recommendations Tuesday night designed to improve oversight of the U.S. device industry, including the government's ability to revoke approval for products that prove unsafe or ineffective" (Perrone, 8/3).
VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced the publication of preclinical data in the Journal of Neuroimmunology finding that its lead development candidate VB-201 significantly delayed the onset and severity of experimental autoimmune encephalomyelitis (EAE) in mice, the commonly used Multiple sclerosis.
The results from comparative analysis of this population demonstrate the risk of developing dementia increased by 50% for subjects who consumed benzodiazepines during the follow-up period, compared with those who had never used benzodiazepines.
A laboratory study led by UNC medical oncologist Stergios Moschos, MD, demonstrates how a new targeted drug, Elesclomol, blocks oxidative phosphorylation, which appears to play essential role in melanoma that has not been well-understood. Elesclomol (Synta Pharmaceuticals, Lexington, MA) was previously shown to have clinical benefit only in patients with normal serum lactate dehydrogenase (LDH), a laboratory test routinely used to assess activity of disease.
› Verified 9 days ago
Shawna Brown, PPCNP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 1006 N H St, Aberdeen, WA 98520 Phone: 360-537-6430 | |
Patricia Kay Lokken, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 615 North F Street, Aberdeen, WA 98520 Phone: 360-533-4599 Fax: 360-267-0417 | |
Melissa Ann Mcfarland, ARNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 511 W Heron St, Aberdeen, WA 98520 Phone: 564-544-1950 | |
Melody Albano, DNP, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1006 N H St, Aberdeen, WA 98520 Phone: 866-537-2778 | |
Ms. Katha Suzanne Gazda, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1006 N H St, Aberdeen, WA 98520 Phone: 360-537-6496 | |
Mr. Nathan Howard Valentine, FNP-BC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1020 Anderson Dr Ste 203, Aberdeen, WA 98520 Phone: 360-533-6063 | |
Mr. Ronald Scott Oman, ARNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 1006 N H St, Aberdeen, WA 98520 Phone: 360-537-6332 Fax: 360-537-6322 |